- Topic1/3
12k Popularity
13k Popularity
19k Popularity
5k Popularity
21k Popularity
- Pin
- #Gate 2025 Semi-Year Community Gala# voting is in progress! 🔥
Gate Square TOP 40 Creator Leaderboard is out
🙌 Vote to support your favorite creators: www.gate.com/activities/community-vote
Earn Votes by completing daily [Square] tasks. 30 delivered Votes = 1 lucky draw chance!
🎁 Win prizes like iPhone 16 Pro Max, Golden Bull Sculpture, Futures Voucher, and hot tokens.
The more you support, the higher your chances!
Vote to support creators now and win big!
https://www.gate.com/announcements/article/45974
- 🎉 Hey Gate Square friends! Non-stop perks and endless excitement—our hottest posting reward events are ongoing now! The more you post, the more you win. Don’t miss your exclusive goodies! 🚀
1️⃣ #ETH Hits 4800# | Market Analysis & Prediction: Boldly share your ETH predictions to showcase your insights! 10 lucky users will split a 0.1 ETH prize!
Details 👉 https://www.gate.com/post/status/12322612
2️⃣ #Creator Campaign Phase 2# |ZKWASM Topic: Share original content about ZKWASM or its trading activity on X or Gate Square to win a share of 4,000 ZKWASM!
Details 👉 https://www.gate.com/post/st
Biopharmaceutical company Liminatus announces its entry into the encryption field with plans to invest $500 million in BNB.
On July 28, according to reports, the clinical-stage biopharmaceutical company Liminatus Pharma, Inc. (NASDAQ: LIMN) announced today its plan to strategically expand into the Crypto Assets and Blockchain sectors.
The company plans to establish a subsidiary named "American BNB Strategy" to lead its digital asset investment and management program. Through this platform, Liminatus aims to raise and deploy up to $500 million in a phased manner, with the goal of making strategic long-term investments in BNB.
Liminatus emphasizes that although the company continues to fully invest in its core business - advancing cancer treatment and the development of pancreatic cancer diagnostic technologies, it believes that expanding into the digital asset space is a necessary step to support long-term growth and enhance shareholder value.
Liminatus is a preclinical biopharmaceutical company dedicated to developing immunotherapies for cancer patients. The company is advancing a series of novel therapies targeting cancer antigens and tumor-specific immune responses.